生命科学资讯
生物技术与制药领域的最新动态
Moderna遭FDA拒收信函针对mRNA流感疫苗,强烈反驳监管机构理由。
Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
凯莱拉与恒瑞宣布肥胖症药物中期研究显示减重效果可达12%。
Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
Evommune类似Dupixent的二期湿疹数据推动股价飙升75%
Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally
默克联手英国医疗科技公司,提升阴道治疗给药系统。
Merck teams up with British medtech to boost vaginal therapeutics delivery system
阿斯利康口服GLP-1药物二期试验成功,但暂未公布减重数据。
AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
Nektar湿疹候选药物在长期二期数据中“满足所有条件”。
Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data
百时美施贵宝与Evinova签署全球开发合作协议
Bristol Myers and Evinova pen global development partnership
FDA拒绝批准Regenxbio公司亨特综合征基因疗法,CEO表示“担忧”。
FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned'
FDA对强生医疗科技Cerepak可拆卸线圈发出最高风险召回通知。
FDA slaps highest-risk recall notice on J&J Medtech Cerepak detachable coils
武田制药与Iambic Therapeutics签署17亿美元AI药物发现协议。
Takeda inks $1.7B AI drug discovery deal with Iambic Therapeutics
礼来以24亿美元收购Orna,进军体内CAR-T领域。
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena
礼来与信达生物达成88亿美元肿瘤及免疫学合作,超越传统授权模式。
Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'
CSL签署3.28亿美元研究合作,可选择Memo的免疫球蛋白抗体技术。
CSL signs on to $328M research collab with option for Memo’s immunoglobulin antibody tech
人工智能如何重塑临床试验与市场准入
How AI Is reshaping clinical trials and market access
数据倍增效应:当专业知识、监控、系统与人工智能协同一致时
The Data Multiplier Effect: When Expertise, Monitoring, Systems, and AI Align
UniQure暂停两组法布里病基因疗法给药,因毒性问题显现。
UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge
新披露显示,罗氏基因泰克去年裁员至少489人。
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
辉瑞支持的Priovant公司凭借快速崛起的brepocitinib在中期研究中再获佳绩。
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
莫德纳首席营销官在领导层变动中离职。
Chutes & Ladders—Moderna CMO steps down in leadership mix-up